Lauren Mastrocola net worth and biography

Lauren Mastrocola Biography and Net Worth

Lauren Mastrocola is currently working as the Chief Accounting Officer & Vice President-Finance at Praxis Precision Medicines, Inc.

What is Lauren Mastrocola's net worth?: The estimated net worth of Lauren Mastrocola is at least $208,242.30 as of November 14th, 2024. Mastrocola owns 5,613 shares of Praxis Precision Medicines stock worth more than $208,242 as of May 15th. This net worth estimate does not reflect any other assets that Mastrocola may own. Learn More about Lauren Mastrocola's net worth.
How do I contact Lauren Mastrocola?: The corporate mailing address for Mastrocola and other Praxis Precision Medicines executives is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. Praxis Precision Medicines can also be reached via phone at 617-300-8460 and via email at investors@praxismedicines.com. Learn More on Lauren Mastrocola's contact information.
Has Lauren Mastrocola been buying or selling shares of Praxis Precision Medicines?: Lauren Mastrocola has not been actively trading shares of Praxis Precision Medicines over the course of the past ninety days. Most recently, Lauren Mastrocola sold 5,188 shares of the business's stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $81.78, for a transaction totalling $424,274.64. Following the completion of the sale, the insider now directly owns 5,613 shares of the company's stock, valued at $459,031.14. Learn More on Lauren Mastrocola's trading history.
Who are Praxis Precision Medicines' active insiders?: Praxis Precision Medicines' insider roster includes Jill Desimone (Director), Lauren Mastrocola (Insider), Alex Nemiroff (General Counsel), and Marcio Souza (CEO). Learn More on Praxis Precision Medicines' active insiders.
Are insiders buying or selling shares of Praxis Precision Medicines?: In the last twelve months, insiders at the sold shares 2 times. They sold a total of 13,427 shares worth more than $1,085,042.44. The most recent insider tranaction occured on November, 14th when General Counsel Alex Nemiroff sold 8,239 shares worth more than $660,767.80. Insiders at Praxis Precision Medicines own 2.7% of the company. Learn More about insider trades at Praxis Precision Medicines.
Information on this page was last updated on 11/14/2024.

Lauren Mastrocola Insider Trading History at Praxis Precision Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/14/2024	Sell	5,188	$81.78	$424,274.64	5,613
6/16/2022	Buy	200	$28.95	$5,790.00	2,092

Lauren Mastrocola Buying and Selling Activity at Praxis Precision Medicines

Praxis Precision Medicines Company Overview

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Today's Range

Now: $37.10

$35.41

$37.96

50 Day Range

MA: $35.59

$28.47

$40.24

2 Week Range

Now: $37.10

$26.70

$91.83

Volume

277,328 shs

Average Volume

388,698 shs

Market Capitalization

$755.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.65